The Drug-Induced Respiratory Disease Website and App

I. Interstitial/parenchymal lung disease

I.a Pneumonitis (ILD)

I. Interstitial/parenchymal lung disease

I.e Organizing pneumonia pattern (an area or areas of consolidation on imaging)

IV. Airway involvement

IV.a Bronchospasm - Wheezing - Asthma

IV. Airway involvement

IV.b Severe or catastrophic bronchospasm or asthma attack (can be fatal)

VI. Pleural and/or pericardial involvement

VI.a Pleural effusion (uni- or bilateral) (can accompany DI-LDs)

VI. Pleural and/or pericardial involvement

VI.c Pleural thickening - Fibrothorax

VI. Pleural and/or pericardial involvement

VI.d Pleural/pericardial effusion, ANA positive (DI lupus)

X. Systemic/Distant conditions, syndromes and reactions

X.aa Subclinical ANA positivity

I. Interstitial/parenchymal lung disease

I.c Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)

II. Pulmonary edema - Acute lung injury - ARDS

II.e ARDS - Acute lung injury

VI. Pleural and/or pericardial involvement

VI.b Eosinophilic pleural effusion

X. Systemic/Distant conditions, syndromes and reactions

X.a DRES syndrome - DRESS-like reaction

X. Systemic/Distant conditions, syndromes and reactions

X.b Antiphospholipid antibodies w/wo the APL syndrome

X. Systemic/Distant conditions, syndromes and reactions

X.aa Subclinical ANA positivity

XI. Miscellaneous

XI.y Gingival hypertrophy

XX. Infections & related conditions

XX.v Hypogammaglobulinemia - Antibody deficiency

I. Interstitial/parenchymal lung disease

I.a Pneumonitis (ILD)

I. Interstitial/parenchymal lung disease

I.e Organizing pneumonia pattern (an area or areas of consolidation on imaging)

VI. Pleural and/or pericardial involvement

VI.a Pleural effusion (uni- or bilateral) (can accompany DI-LDs)

X. Systemic/Distant conditions, syndromes and reactions

X.d Lupus - Lupus syndrome (see also Vd)

X. Systemic/Distant conditions, syndromes and reactions

X.u Vasculitis, pulmonary (w/wo AH), extrapulmonary, systemic: ANCA-positive

X. Systemic/Distant conditions, syndromes and reactions

X.aa Subclinical ANA positivity

I. Interstitial/parenchymal lung disease

I.a Pneumonitis (ILD)

I. Interstitial/parenchymal lung disease

I.b Pneumonitis (ILD), acute and/or severe (may cause ARDS)

I. Interstitial/parenchymal lung disease

I.c Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)

I. Interstitial/parenchymal lung disease

I.e Organizing pneumonia pattern (an area or areas of consolidation on imaging)

I. Interstitial/parenchymal lung disease

I.g Pulmonary fibrosis

I. Interstitial/parenchymal lung disease

I.v Relapsing or migrating pneumonitis/pneumonia (see also Id)

II. Pulmonary edema - Acute lung injury - ARDS

II.a Pulmonary edema, noncardiogenic (NCPE)

IV. Airway involvement

IV.a Bronchospasm - Wheezing - Asthma

IV. Airway involvement

IV.b Severe or catastrophic bronchospasm or asthma attack (can be fatal)

IV. Airway involvement

IV.c Exacerbation or deterioration of preexisting asthma

IV. Airway involvement

IV.d Exacerbation or deterioration of preexisting COPD

VI. Pleural and/or pericardial involvement

VI.a Pleural effusion (uni- or bilateral) (can accompany DI-LDs)

VI. Pleural and/or pericardial involvement

VI.c Pleural thickening - Fibrothorax

VI. Pleural and/or pericardial involvement

VI.d Pleural/pericardial effusion, ANA positive (DI lupus)

VII. Pulmonary vasculopathy

VII.v Worsening of preexisting PHTn

IX. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

IX.d Respiratory failure from ventilatory depression (due to neuromuscular blockade/paralysis)

X. Systemic/Distant conditions, syndromes and reactions

X.d Lupus - Lupus syndrome (see also Vd)

X. Systemic/Distant conditions, syndromes and reactions

X.aa Subclinical ANA positivity

XI. Miscellaneous

XI.o Death following exposure or poisoning

XI. Miscellaneous

XI.ac Refractoriness to epineprine in case of anaphylaxis

XII. Cardiovascular involvement / toxicity

XII.o Cardiovascular collapse - Cardiogenic shock - Hypotension

XII. Cardiovascular involvement / toxicity

XII.u Cardiac- cardiorespiratory/pulmonary arrest

XII. Cardiovascular involvement / toxicity

XII.ah Coronary vasospasm - Vasospastic angina

VI. Pleural and/or pericardial involvement

VI.d Pleural/pericardial effusion, ANA positive (DI lupus)

VIII. Mediastinal involvement

VIII.b Lymphadenopathy with reactive changes

X. Systemic/Distant conditions, syndromes and reactions

X.d Lupus - Lupus syndrome (see also Vd)

X. Systemic/Distant conditions, syndromes and reactions

X.o Vascultis (pulmonary, extrathoracic or systemic)-ANCA status unknown or negative)

X. Systemic/Distant conditions, syndromes and reactions

X.aa Subclinical ANA positivity

XI. Miscellaneous

XI.c Pleuritic chest pain

XII. Cardiovascular involvement / toxicity

XII.d Myocarditis (can be fulminant)

XXI. Neoplastic conditions

XXI.b Lymphoproliferative disease (pulmonary, endobronchial, endothoracic)